Creative Planning’s Crinetics Pharmaceuticals CRNX Stock Holding History

Creative Planning’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Sell	40,476 -13,161	-25%	-$489K	﹤0.01%	2316
2026 Q1	$1.95M	Buy	53,637 +6,316	+13%	+$282K	﹤0.01%	1903
2025 Q4	$2.2M	Buy	47,321 +6,749	+17%	+$300K	﹤0.01%	1651
2025 Q3	$1.69M	Buy	40,572 +12,103	+43%	+$387K	﹤0.01%	1671
2025 Q2	$819K	Sell	28,469 -1,445	-5%	-$44.6K	﹤0.01%	2026
2025 Q1	$1M	Buy	29,914 +3,078	+11%	+$115K	﹤0.01%	1712
2024 Q4	$1.37M	Buy	26,836 +7,028	+35%	+$393K	﹤0.01%	1404
2024 Q3	$1.01M	Buy	19,808 +6,811	+52%	+$351K	﹤0.01%	1500
2024 Q2	$582K	Buy	12,997 +2,224	+21%	+$103K	﹤0.01%	1827
2024 Q1	$504K	Buy	+10,773	New	+$422K	﹤0.01%	1842

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's CRNX Position: Q2 2026 in Review

Creative Planning reduced its Crinetics Pharmaceuticals (CRNX) stake by 25% in Q2 2026, selling an estimated $489K and leaving 40,476 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Creative Planning first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.2M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Creative Planning held 40,476 shares of Crinetics Pharmaceuticals worth $1.51M as of Q2 2026.
Creative Planning sold 13,161 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $489K.
Crinetics Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2316 holding.
Creative Planning first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Creative Planning's Crinetics Pharmaceuticals position peaked at $2.2M in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.